B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of cd4+ t-cell clonality in chronic lymphocytic leukemia

Haematologica

Volumn 100, Issue 8, 2015, Pages

  Zaborsky, Nadja ^a,b   Holler, Claudia ^a,b   Geisberger, Roland ^a,b   Asslaber, Daniela ^a,b   Gassner, Franz Josef ^a,b   Egger, Viktoria ^a,b   Piñón Hofbauer, Josephina ^a,b   Kocher, Thomas ^a,b   Hartmann, Tanja Nicole ^a,b   Greil, Richard ^a,b   Egle, Alexander ^a,b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Salzburg Cancer Research Institute   (Austria)

Author keywords

B cell receptor usage; CD4 positive; CD40 stimulation; Chronic lymphocytic leukemia; T cell clonality

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; T LYMPHOCYTE RECEPTOR; COMPLEMENTARITY DETERMINING REGION; IMMUNOGLOBULIN HEAVY CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LETTER; RISK FACTOR; UPREGULATION; CLONAL EVOLUTION; COMPLEMENTARITY DETERMINING REGION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION;

ANTIGENS, CD40; CD4-POSITIVE T-LYMPHOCYTES; CLONAL EVOLUTION; COMPLEMENTARITY DETERMINING REGIONS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; RECEPTORS, ANTIGEN, B-CELL;

EID: 84938599619     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124719     Document Type: Letter

References (9)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847.
2. Weinberg JB, Volkheimer AD, Chen Y, et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol. 2007;82(12):1063-1070.
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
4. Darzentas N, Stamatopoulos K. The Significance of Stereotyped BCell Receptors in Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2013;27(2):237-250.
5. Gassner FJ, Zaborsky N, Neureiter D, et al. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica. 2014;99(5):67-69.
6. Nunes C, Wong R, Mason M, et al. Expansion of a CD8 (+)PD-1(+) Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression. Clin Cancer Res. 2012;18(3):678-687.
7. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
8. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612-1621.
9. Baliakas P, Hadzidimitriou A, Sutton L, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: A retrospective multicentre study. Lancet Haematol. 2014; 1(2):e74-e84.